NLS Pharmaceutics Announces Merger With Kadimastem to Create NewcelX

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Complete Merger to Form NewcelX Ltd.

October 30, 2025

Biotechnology

NLS Pharmaceutics Ltd. and Kadimastem Ltd. completed their previously announced merger under an Agreement of Merger and Plan of Reorganization dated November 4, 2024. The combined company was renamed NewcelX Ltd. and began trading on the Nasdaq Capital Market on October 31, 2025 under ticker “NCEL.”

Norstella and Citeline Merge to Create $5B Global Pharma Technology Company

June 28, 2022

Data & Analytics

Norstella (the group of Evaluate, MMIT, Panalgo and The Dedham Group) announced an agreement to merge with Citeline (formerly Pharma Intelligence) to form a combined global pharmaceutical technology and intelligence business valued at about $5 billion. The combination brings clinical trial intelligence, commercial data and real‑world analytics together to offer an end‑to‑end suite of solutions for life sciences companies; the deal involves financial sponsors including Hg (Norstella) and Warburg Pincus (Citeline).

Altaris Combines Kindeva Drug Delivery and Meridian Medical Technologies

December 13, 2022

Medical Devices

Altaris has completed the combination of its portfolio companies Kindeva Drug Delivery and Meridian Medical Technologies into a single, global drug‑device CDMO that will operate under the Kindeva name. The combined company expands capabilities across parenteral, inhalation, transdermal and intradermal delivery formats; Milton Boyer (formerly Meridian CEO) will lead the combined business.

Chroma Medicine and Nvelop Therapeutics Merge to Form nChroma Bio

December 11, 2024

Biotechnology

Chroma Medicine and Nvelop Therapeutics have merged to form nChroma Bio and completed an oversubscribed $75 million financing led by Cormorant Asset Management, ARCH Venture Partners, Atlas Venture and Newpath Partners. The combined company will advance a pipeline built on epigenetic editing and non-viral, programmable in vivo delivery, with lead candidate CRMA-1001 targeted at chronic hepatitis B and D and a planned clinical trial application submission in 2025.

N-Power Medicine Acquires Syapse

December 30, 2024

Healthcare Services

N-Power Medicine completed a stock-for-stock acquisition of Syapse on December 30, 2024, integrating Syapse’s precision-medicine technology, data assets and network of community oncologists into N-Power’s Kaleido Registry and AI-enabled point-of-care platform. Innovatus Capital Partners joined N-Power’s existing investors (including the Merck Global Health Innovation Fund) to provide ongoing funding; Canaccord Genuity served as Syapse’s exclusive financial advisor.

NAMSA to Acquire Belgium-Based Medanex Clinic

March 30, 2022

Healthcare Services

NAMSA, a global MedTech contract research organization (CRO), announced it is nearing the acquisition of Medanex Clinic, a Belgium-based European preclinical research organization. The deal is intended to expand NAMSA’s early-stage preclinical and specifically cardiovascular preclinical capabilities in Europe.